Related by context. All words. (Click for frequent words.) 81 Well Tolerated 81 Adjuvant Therapy 80 Phase IIb Trial 80 Patients Treated 80 Phase III Clinical Trial 80 Meets Primary Endpoint 79 Chronic Hepatitis C 79 Improves Survival 79 Phase 2b Study 78 Previously Treated 78 Elderly Patients 78 Statistically Significant 78 Combination Therapy 78 Clinical Trial Results 78 Study Evaluating 78 Metastatic Colorectal Cancer 78 Tiotropium 78 Combination Treatment 78 Survival Benefit 78 Metastatic Prostate Cancer 77 Disease Progression 77 Improves Outcomes 77 Relapsing Multiple Sclerosis 77 Long Term Efficacy 77 Advanced Prostate Cancer 77 Prolongs Survival 77 Is Well Tolerated 77 Pooled Analysis 77 Unfractionated Heparin 77 Phase 2b Clinical Trial 77 Patients Treated With 77 Zoledronic Acid 77 Oral Fingolimod 77 Phase III Trial 77 Newly Diagnosed Multiple Myeloma 77 Capecitabine 77 Anti Tumor Activity 76 Improved Survival 76 Adjuvant Treatment 76 Adalimumab 76 Infected Patients 76 Versus Placebo 76 Single Dose 76 Protease Inhibitor 76 Treated Patients 76 II Clinical Trial 76 Rheumatoid Arthritis Patients 76 Peginterferon Alfa 2a 76 Controlled Trial 76 Statin Therapy 76 Relapsing Remitting Multiple Sclerosis 76 Advanced Melanoma 76 Drug Candidate 76 Cardiovascular Events 76 Tolerability 75 Relapsed Multiple Myeloma 75 Pivotal Phase 75 Diabetic Patients 75 Postmenopausal Women 75 Renal Cell Carcinoma 75 Study Showed 75 Knee Osteoarthritis 75 Pivotal Phase III 75 Hepatitis C Patients 75 Demonstrated Significant 75 Non Responders 75 Ranolazine 75 Adjuvant Chemotherapy 75 Advanced Renal Cell 75 Significantly Reduced 75 Peginterferon 75 Colorectal Cancer Patients 75 Trial Evaluating 75 Previously Untreated 75 Antitumor Activity 75 Pharmacokinetic Study 75 Preclinical Data 75 Appears Safe 75 Complicated Skin 75 Low Dose 75 Demonstrates Significant 75 Insulin Glargine 75 Phase III Trials 75 Dose Escalation 75 Adjunctive Therapy 75 Investigational Drug 74 Investigational Compound 74 Demonstrates Positive 74 Autologous Stem Cell Transplantation 74 Randomized Double Blind 74 Pivotal Trial 74 Hypertensive Patients 74 Pivotal Study 74 Plus Ribavirin 74 Metastatic Renal Cell Carcinoma 74 Hormone Refractory Prostate Cancer 74 Shows Efficacy 74 Phase 2b Trial 74 Clinical Trial Evaluating 74 Phase IIa Clinical Trial 74 Hormone Receptor Positive 74 Prophylactic Treatment 74 Phase 2a Clinical Trial 74 Inhaled Corticosteroids 74 Patients Receiving 74 Bortezomib 74 JAK Inhibitor 74 Improve Survival 74 Pulmonary Arterial Hypertension 74 Treatment Experienced 74 Severe Sepsis 74 Fondaparinux 74 Castration Resistant Prostate Cancer 74 Efficacious 74 Nilotinib 74 Carboplatin Paclitaxel 74 Investigational Agent 74 Demonstrates Efficacy 74 Phase IIb Clinical Trial 74 Demonstrates Potent 74 Medoxomil 74 Bevacizumab 73 Antiviral Activity 73 Postmenopausal Osteoporosis 73 Completes Enrollment 73 Placebo Controlled Trial 73 Advanced Pancreatic Cancer 73 Significantly Improved 73 Bone Mineral Density 73 Dasatinib 73 Restenosis 73 Overactive Bladder 73 Epoetin Alfa 73 Heart Failure Patients 73 Randomized Phase 73 Prospective Randomized 73 Controlled Study 73 Subgroup Analysis 73 Pediatric Patients 73 Anti Tumor 73 Novel Oral 73 Breast Cancer Recurrence 73 Treatment Naive Patients 73 Patients Undergoing 73 Treatment Naïve 73 Completes Patient Enrollment 73 Lenalidomide 73 Relapsed 73 Cholesterol Lowering Drug 73 Relapsed Refractory 73 Treating Chronic 73 Radical Prostatectomy 73 Diabetic Nephropathy 73 Enoxaparin 73 Chronic Hepatitis B 73 Androgen Deprivation Therapy 73 Treatment Regimen 73 Chemoradiation 72 Fracture Risk 72 Pegylated Liposomal Doxorubicin 72 Pegylated 72 Extended Release 72 Renal Impairment 72 Clinical Efficacy 72 Investigational Treatment 72 Hepatitis C Genotype 72 SPRYCEL ® 72 Interferon Beta 72 Lamotrigine 72 Neoadjuvant Chemotherapy 72 HER2 Positive Breast Cancer 72 Advanced Colorectal Cancer 72 Fludarabine 72 NDA Submission 72 Lung Cancer Trial 72 Metastatic Melanoma 72 Receptor Antagonists 72 Hypercholesterolemia 72 Desvenlafaxine Succinate 72 Patients Suffering 72 Viral Suppression 72 Receives Orphan Drug Designation 72 Novel Mechanism 72 Prostate Cancer Patients 72 Tumor Growth 72 Anti TNF 72 Orally Active 72 Gemcitabine 72 Bosentan 72 Fewer Side Effects 72 Benign Prostatic Hyperplasia 72 Cutaneous T 72 Presents Preclinical Data 72 Trastuzumab 72 Study Demonstrates 72 Anthracycline 72 Seasonal Allergic Rhinitis 72 Double Blind Randomized 72 Myelodysplastic Syndromes 72 Acute Ischemic Stroke 72 Treatment Naive 72 Bosutinib 71 Fixed Dose 71 Radiofrequency Ablation 71 Higher Doses 71 Pioglitazone 71 Bare Metal Stents 71 Aliskiren 71 Plaque Psoriasis 71 Refractory Hodgkin Lymphoma 71 Stent Restenosis 71 Placebo Controlled Study 71 Renal Function 71 Glatiramer Acetate 71 Venous Thromboembolism 71 Irinotecan 71 Partial Onset Seizures 71 Kidney Function 71 Cyclophosphamide 71 Myeloma Patients 71 Double Blind Placebo 71 Mycophenolate Mofetil 71 Osteoporosis Drug 71 Data Suggest 71 Gout Drug 71 Oral Formulation 71 Pegylated Interferon 71 Newly Diagnosed 71 Kidney Transplant Recipients 71 Hemodialysis Patients 71 Neoadjuvant 71 Advanced Ovarian Cancer 71 Pafuramidine 71 Lupus Nephritis 71 Fulvestrant 71 Patient Enrollment 71 Anticancer Activity 71 Glufosfamide 71 Randomized Double Blind Placebo 71 Shows Promising 71 Localized Prostate Cancer 71 Melphalan 71 Resistant Hypertension 71 Naive Patients 71 Paraplatin ® 71 Posaconazole 71 Antitumor 71 Unresectable 71 Pharmacokinetics PK 71 FASLODEX 71 R lenalidomide 71 Increased Risk 71 Chronic Myeloid Leukemia 71 Protease Inhibitors 71 Presents Positive 71 Antipsychotic 71 Interferon beta 1a 71 Capsules CII 71 HCV Protease Inhibitor 71 Multiple Myeloma Patients 71 Sustained Reduction 71 Treatment Resistant 71 Diffuse Large B 71 Platelet Inhibition 70 Lung Cancer Patients 70 Valsartan 70 ritonavir boosted 70 Randomized Clinical Trial 70 Significantly Reduces 70 Nebulized 70 TNF Tumor Necrosis Factor 70 Soft Tissue Sarcoma 70 Vildagliptin 70 Phase 2a Trial 70 Infliximab 70 Blood Pressure Lowering 70 Fungal Infections 70 Dose Finding 70 Hsp# Inhibitor 70 PRN FDA Approves 70 Gene Variant 70 Granted Orphan Drug 70 Recombinant Human 70 dasatinib Sprycel ® 70 Proven Effective 70 alfa 2a 70 Follicular Lymphoma 70 Decitabine 70 TO AVOID PREGNANCY WHILE 70 Present Preclinical Data 70 Nucleoside 70 Ziprasidone 70 Stent Implantation 70 IND Application 70 Receptor Agonist 70 Epratuzumab 70 Disease Modifying 70 Demonstrate Significant 70 Sirolimus Eluting 70 Clinical Outcome 70 Allergic Rhinitis 70 Randomized Study 70 Treatment Naive HIV 70 FDA Okays 70 Initiates Clinical Trial 70 Receptor Antagonist 70 Fluorouracil 70 Serious Infections 70 Kinase Inhibitor 70 Immunosuppression 70 Glycemic Control 70 Treatment Naïve Patients 70 Combination REOLYSIN R 70 Interferon Alfa 70 Dose Ranging Study 70 Mg Usa 70 Meta Analysis 70 Sirolimus Eluting Stent 70 PEGylated Fab fragment 70 Generic Version 70 Lipid Levels 70 Pemetrexed 70 Bivalirudin 70 Achieves Primary Endpoint 70 Beneficial Effects 70 Aflibercept 70 ACE Inhibitors 70 Lupus Drug 70 Combo Therapy 70 Significantly Improves 70 Reduced Incidence 70 Lacosamide 70 Blood Pressure Drug 70 Glucose Control 70 Reduced Risk 70 Advanced Solid Tumors 70 Mylan Receives Approval 70 Dual Antiplatelet Therapy 70 Tocilizumab 70 PEGINTRON TM 70 Chronic Sinusitis 70 Erlotinib 70 Liver Failure 70 Adefovir 69 Phase III Clinical Trials 69 Osteoporosis Drugs 69 Chemotherapy Induced 69 Phospholipase A2 69 Treatment Reduces 69 Significant Efficacy 69 Left Ventricular 69 Metabolic Efficiency 69 Menopausal Women 69 Severe Asthma 69 Kidney Transplant Patients 69 Improve Outcomes 69 Fast Track Status 69 Epilepsy Drug 69 Randomized Double blind 69 Sustained Virologic Response 69 Diuretic 69 Initiate Phase 69 Anticoagulant 69 Tezampanel 69 Novel Antibiotic 69 NICE Recommends 69 Natalizumab 69 Malignant Glioma 69 Atypical Antipsychotic 69 Aurora Kinase 69 Safinamide 69 Randomized Controlled Trial 69 Interferon Gamma 69 Metastatic Pancreatic Cancer 69 Mouse Model 69 Cardiovascular Outcomes 69 Proves Effective 69 Reduces Risk 69 Submits NDA 69 Non Inferiority 69 Predict Risk 69 Nymox NX 69 Efficacy Trial 69 Initiate Clinical Trial 69 Golimumab 69 FDA Approvals 69 Chronic Heart Failure 69 Insulin Resistance 69 Carotid Stenting 69 Estrogen Therapy 69 JAK2 Inhibitor 69 Progressive Multifocal Leukoencephalopathy 69 Gemzar ® 69 Placebo Controlled 69 5 FU leucovorin 69 First Patient Dosed 69 Alpha interferons including 69 Gene Mutation 69 Etanercept 69 Hyperlipidemia 69 FDA Approves 69 Traficet EN 69 Regimens 69 Commonly Used 69 Brain Metastases 69 Rotavirus Vaccine 69 Lung Cancers 69 Bipolar Depression 69 Diabetic Neuropathic Pain 69 ORENCIA ® 69 Expanded Indication 69 Peginterferon Alfa 2b 69 Investigational Oral 69 Novel Inhibitor 69 Mesalamine 69 FDA Accepts 69 XYOTAX TM 69 Telbivudine 69 Clopidogrel 69 Effective Than 69 HDAC Inhibitor 69 Long Term Outcomes 69 oral prodrug 69 Randomized Placebo Controlled Trial 69 Phase III Pivotal Trial 69 PEGylated anti 69 sunitinib Sutent ® 69 Vicriviroc 69 Immune Responses 69 Cognitive Impairment 69 Breast Cancer Patients 69 Randomized Controlled Trials 69 Randomised Trial 69 Replacement Therapy 69 Files IND 69 Low Density Lipoprotein Cholesterol 69 Moxifloxacin 69 Randomized Phase II 69 See CLINICAL PHARMACOLOGY 69 Tipranavir 69 Dapagliflozin 69 Effectively Treats 69 Mg Uk 69 Hospital Acquired Pneumonia 69 Cell Lymphoma 69 Malignant Melanoma 69 FOLFOX6 69 Immunogenic 69 HCV Genotype 69 Phase 1b Clinical Trial 69 Universal Flu Vaccine 69 Atypical Hemolytic Uremic Syndrome 69 Lowers Risk 69 FEMALES SHOULD BE ADVISED 69 Showed Significant 69 Secondary Hyperparathyroidism 69 Liver Metastases 69 Tyrosine Kinase Inhibitor 69 ribavirin RBV 68 Teva Provides Update 68 Corticosteroid 68 Cyclooxygenase 2 68 Chronic Constipation 68 Sulfonylurea 68 Sorafenib 68 Drug Shows Promise 68 adalimumab Humira 68 Ischemic Stroke 68 Abciximab 68 Shows Promise 68 Tumor Necrosis Factor 68 Prophylaxis 68 Lanthanum Carbonate 68 Voreloxin 68 Percutaneous Coronary Intervention 68 RNAi Therapeutic 68 alpha 2a 68 Methylnaltrexone 68 Increases Risk 68 Pharmacokinetic 68 Inhalation Aerosol 68 Combination Clinical Trial 68 Epidermal Growth Factor Receptor 68 Sustained Efficacy 68 Breast Cancer Treatment 68 Therapeutic Potential 68 dual endothelin receptor antagonist 68 leukotriene receptor antagonist 68 Dose Response 68 Enlarged Prostate 68 Atypical Antipsychotics 68 Viral Load 68 Osteoarthritis Patients 68 Gene Variation 68 Node Positive 68 Testosterone Gel 68 Cardiotoxicity 68 Slow Progression 68 Spectrum Pharmaceuticals Announces 68 Sapacitabine 68 Taxane 68 Symptom Relief 68 Cholesterol Drugs 68 Cilostazol 68 Gastric Cancer 68 FOLFIRI 68 Zileuton 68 Based Regimens 68 Beta Blocker 68 Shows Promise Against 68 Darunavir 68 Septic Shock 68 Initiates Phase 68 VAPRISOL 68 Montelukast 68 Subcutaneous 68 Induces 68 Betaferon R 68 Thromboembolism 68 Invasive Fungal Infections 68 Potent Antiviral Activity 68 TAXOTERE R 68 Lung Cancer Drug 68 MEK Inhibitor 68 administered concomitantly 68 Patients Enrolled 68 Critically Ill Patients 68 Pivotal Trials 68 AZILECT R 68 Positive Opinion 68 Bicalutamide 68 Endometrial Cancer 68 Antidepressant Drug 68 Cardiac Resynchronization 68 Itraconazole 68 CIMZIA R 68 Phase 2a Study 68 Vaginal Gel 68 Azacitidine 68 Certolizumab 68 erlotinib Tarceva ® 68 Telaprevir VX 68 docetaxel Taxotere ® 68 administered subcutaneously 68 Humanized Anti 68 Coadministration 68 Hormone Therapy 68 Solid Tumors 68 Breast Cancers 68 Hepatocellular Carcinoma 68 Taxotere ® 68 Preclinical Study 68 Inhibits 68 Initiates Phase III 68 Relapsed Refractory Multiple Myeloma 68 Chemotherapy Regimen 68 Partial Seizures 68 Randomised 68 Tesamorelin 68 Acute Migraine 68 gefitinib Iressa 68 Neuroprotective Effects 68 ergot derivatives 68 evaluating tivozanib 68 Initiates Enrollment 68 Chemotherapy Improves 68 Osteoporosis Treatment 68 leukopenia pancytopenia thrombocytopenia 68 Slows Progression 68 Ozarelix 68 Receives Positive Opinion 68 Emerging Therapies 68 Therapy Reduces 68 Enzyme Replacement Therapy 68 Physical Function 68 Remission Maintenance 68 Confirms Efficacy 68 First Patient Enrolled 68 Disease Severity 68 Adenoma Prevention 68 Attenuates 68 Diabetic Neuropathy 68 Increased Mortality 68 Hematological Cancers 68 Drug Resistant 68 Major Depressive Disorder 68 Pharmacodynamics 68 Interferon Alpha 68 Initiate Phase III 68 Presents Preclinical 68 PKC# 68 Acute Coronary Syndromes 68 Minimally Invasive Treatment 68 Nicotine Vaccine 68 Intravenous Formulation 68 Tumor Progression 68 Brentuximab Vedotin SGN 68 Primary Hypercholesterolemia 68 Invasive Breast Cancer 67 ST Elevation Myocardial 67 Adverse Effects 67 Suicidality 67 Dose Ranging 67 Premenopausal Women 67 Colorectal Adenomas 67 Drug Combo 67 Risedronate 67 Vaccine Candidate 67 Known hypersensitivity 67 aripiprazole Abilify 67 investigational oral inhibitor 67 Clinical Study 67 Paclitaxel Carboplatin 67 Clostridium difficile Infection 67 Xanafide 67 APTIVUS r 67 CIMZIA TM 67 Endovascular Treatment 67 Tigecycline 67 Suppresses 67 Migraine Drug 67 Generalized Anxiety Disorder 67 LEXIVA 67 Imatinib 67 Monoclonal Antibody 67 Cognitive Decline 67 Ofatumumab 67 Hemoglobin Levels 67 Premature Infants 67 Dendritic Cells 67 TRANSFORMS 67 Esomeprazole 67 brand ciclesonide HFA 67 Initiates Clinical 67 Juvenile Idiopathic Arthritis 67 RoACTEMRA 67 EGFR TKI 67 APTIVUS 67 Fluticasone 67 Therapy Improves 67 Eszopiclone 67 REVLIMID R 67 Pegloticase 67 #mg BID [003] 67 Randomized Evaluation 67 Beta Blockers 67 Alemtuzumab 67 Eculizumab 67 Valproic Acid 67 Orthostatic Hypotension 67 Sitagliptin 67 Polymerase Inhibitor 67 Reduces Pain 67 BARACLUDE ® 67 Chronic HCV 67 Corticosteroids 67 Topline Results 67 Oral Calcitonin 67 Prostate Cancer Vaccine 67 FDA Clears 67 Ramipril 67 5 Fluorouracil 67 Skeletal Muscle 67 Confirmatory Phase 67 Vaccine Adjuvant 67 Ischemic 67 Trodusquemine MSI 67 Molecular Weight Heparin 67 Dupuytren Contracture 67 Docetaxel 67 Pivotal Clinical Trial 67 Sandostatin R 67 Novel Compound 67 Cholinesterase Inhibitors 67 Ovarian Cancer Patients 67 Sipuleucel T 67 FDA APPROVES 67 Daptomycin 67 Quetiapine 67 fosbretabulin 67 STELARA TM 67 Experimental Vaccine 67 Demonstrates Potential 67 Randomized Trials 67 BRIM2 67 Gout Patients 67 Collaborators Present 67 Clinical Study Shows 67 abacavir sulfate lamivudine 67 Darbepoetin Alfa 67 Parathyroid Hormone 67 Sangamo BioSciences Announces 67 Schizophrenia Drug 67 3TC lamivudine Epivir 67 Dose Escalation Study 67 icatibant 67 Inhalation Solution 67 Transdermal Patch 67 Chronic Lymphocytic Leukemia 67 Panic Disorder 67 Blood Thinner 67 Salmeterol 67 Human Monoclonal Antibody 67 Signaling Pathway 67 Vitro Activity 67 pioglitazone HCl 67 Levels Linked 67 Granulocyte Colony Stimulating Factor 67 Platinol ® 67 Treating Heart Failure 67 Antiviral Drugs 67 Inflammatory Markers 67 Diabetic Foot Ulcer 67 CCX# B 67 ribavirin USP 67 Induction Chemotherapy 67 atazanavir sulfate 67 NOXAFIL 67 Prognostic Significance 67 Lamivudine 67 Mitoxantrone 67 metastatic malignant 67 Myelodysplastic Syndrome MDS 67 sapropterin dihydrochloride 67 rilonacept 67 Extended Release Formulation 67 Pneumococcal Vaccine 67 Clinical Trial Data 67 Sevelamer 67 receptor tyrosine kinase inhibitor 67 Hepatotoxicity 67 Patent Covering 67 Maribavir 67 Erectile Dysfunction Drug 67 Acute Pancreatitis 67 Severe Psoriasis 67 PEG IFN 67 Unstable Angina 67 Arthritis Drug 67 Lubiprostone 67 8mg/kg 67 Potentially Fatal 67 Demonstrates Statistically Significant 67 Hemolysis 67 Dialysis Patients 67 Analogs 67 Calcitonin 67 Cholesterol Levels 67 Anti Clotting Drug 67 Meet Primary Endpoint 67 Lipid Lowering 67 Cognitive Function 67 Obese Patients 67 mycophenolate mofetil 67 Metastatic Breast Cancer 67 oral antidiabetic medication 67 Boceprevir 67 Late Breaker 67 Demonstrates Sustained 67 Cardiac Function 67 Tolvaptan 67 Denufosol 67 Hepatic Impairment 67 Antiplatelet Therapy 67 Uric Acid 67 Rheumatoid Arthritis Drug 67 Tumor Response 67 Treat Anemia 67 Antiangiogenic 67 Left Ventricular Dysfunction 67 Complete Remission 66 Mayo Clinic Study Finds 66 evaluating picoplatin 66 Gene Linked 66 Virologic 66 Migraine Pain 66 imatinib Gleevec ® 66 Adjunctive 66 Recurrent Ovarian Cancer 66 Factor Xa Inhibitor 66 interferon gamma 1b 66 unfractionated heparin UFH 66 Eltrombopag 66 ADHD Medication 66 Commonly Prescribed 66 CAELYX 66 Controlled Clinical Trial 66 Pegasys ® 66 Drug Fails 66 ACTEMRA TM 66 CONTRAINDICATIONS 66 Tablet Formulation 66 Immunomodulatory 66 Ambrisentan 66 Prostate Biopsy 66 Clinical Evaluation 66 Phase IIa Trial 66 ANDA Filing 66 Xeloda ® 66 Linagliptin 66 Oral Cladribine 66 DOXIL 66 Inhaled Nitric Oxide 66 Anti Inflammatory Drug 66 Preterm Delivery 66 Acute Myocardial Infarction 66 Intravitreal 66 B Cell Malignancies 66 Patient Outcomes 66 Cardiogenic Shock 66 R bisoprolol Euthyrox 66 Telithromycin 66 bone marrow reticulin deposition 66 Tacrolimus 66 CYP#A# substrate 66 Potent Anti 66 Lung Function 66 Renal Insufficiency 66 R pioglitazone HCl 66 Elotuzumab 66 Myelofibrosis 66 Myocardial Ischemia 66 mGluR5 negative 66 tocilizumab 66 Bisphosphonate 66 Dosed 66 sertraline Zoloft 66 Cethromycin 66 FDA Panel Recommends 66 selective modulator 66 Elevated Levels 66 Exemestane 66 TNF Blockers 66 HMG CoA reductase inhibitors 66 Aptivus ® 66 Bone Metastases 66 AVASTIN 66 Angiogenic 66 Victoza R 66 Aromatase Inhibitors 66 Systemic Sclerosis 66 Oral Contraceptives 66 Cocaine Addiction 66 Chronic Renal Failure 66 cell lymphoma CTCL 66 FUSILEV enhances 66 Prospective Randomized Trial 66 Efficacy 66 Eluting Stent 66 Zoloft sertraline 66 Catheter Ablation 66 coadministration 66 IND Filing 66 Recurrent Breast Cancer 66 Peginterferon alfa 2b 66 venlafaxine Effexor 66 Initiates Phase II 66 Allogeneic 66 Drug Eluting 66 Rituximab 66 Lung Cancer Survival 66 metastatic castration resistant 66 cinacalcet 66 Tasimelteon 66 Telmisartan 66 PEGylated interferon beta 1a 66 Prodrug 66 Lowers Blood Pressure 66 Phase III Pivotal 66 Thyroid Hormone 66 Allergic Reactions 66 Ocrelizumab 66 Dexamethasone 66 Microplasmin 66 Romiplostim 66 ® lenalidomide 66 stage IIIB 66 Laquinimod 66 R# #mg BID 66 Depressive Symptoms 66 antiplatelet agent 66 moderate hepatic impairment 66 Intravesical 66 CYP#A# CYP#D# 66 alkylating agent 66 Menopausal Symptoms 66 HER2 Positive 66 liposomal formulation 66 Zorbtive TM 66 Potent Inhibitor 66 Idiopathic Pulmonary Fibrosis 66 Blood Clots 66 Retreatment 66 Bipolar Mania 66 Parenteral Nutrition 66 thalidomide Thalomid 66 alefacept 66 Inflammatory Arthritis 66 myelodysplastic myeloproliferative diseases 66 Artery Disease 66 Aggressive Prostate Cancer 66 Recurrent Glioblastoma 66 Hip Fractures 66 cetuximab Erbitux R 66 Angioedema 66 LANTUS R 66 Secondary Endpoints 66 INVEGA ® 66 abacavir Ziagen 66 Ribavirin 66 C Reactive Protein 66 Primary Endpoint 66 Induction Therapy 66 Acute Heart Failure 66 topical gel formulation 66 Antifungal 66 Anemia Drug 66 Hematological Malignancies 66 ARIXTRA 66 Antiretroviral Therapy 66 Iron Deficiency 66 BARACLUDE R 66 Hepatitis B Vaccine 66 miconazole Lauriad ® 66 Virus Infection 66 Metabolic Disorder 66 Schizophrenia Treatment 66 dependent kinase inhibitor 66 pharmacokinetic interactions 66 Chronic Pelvic Pain 66 Overweight Obese 66 Phase Ib Clinical Trial 66 REVLIMID lenalidomide 66 Psoriasis Drug 66 Respiratory Virus 66 Postherpetic Neuralgia 66 Stem Cell Transplants 66 Reduce Mortality 66 Renal Tumors 66 vapreotide acetate 66 Advanced Gastric Cancer 66 estramustine 66 sorafenib tablets 66 Free Survival PFS 66 Blinatumomab 66 FOLFOX6 chemotherapy regimen 66 Pregnancy Linked 66 Budesonide 66 Oral Spray 66 divalproex sodium 66 Hepatitis C Virus 66 investigational humanized monoclonal antibody 66 Oral Anticoagulant 66 Oritavancin 66 Levofloxacin 65 Hepatic Encephalopathy 65 REYATAZ ® 65 Interferon beta 1b 65 See CONTRAINDICATIONS 65 Cholesterol Drug 65 IN PATIENTS WITH 65 Ondansetron Injection USP 65 Fluconazole 65 Receives Approvable Letter 65 Randomized Clinical Trials 65 Cisplatin 65 CYT# potent vascular disrupting 65 Reduces Mortality 65 Gastric Ulcers 65 Initiates Clinical Trials 65 Bare Metal Stent 65 Successfully Completes Phase 65 Orphan Status 65 Left Ventricular Hypertrophy 65 peripherally acting 65 Therapeutic Efficacy 65 KRN# 65 Renal Cancer 65 Romidepsin 65 First Patient Treated 65 ULORIC 65 REVLIMID ® 65 Cardiovascular Mortality 65 Epileptic Seizures 65 pan HDAC inhibitor 65 Gefitinib 65 Progenitor Cells 65 BENICAR HCT 65 TYKERB 65 Oral Mucositis 65 Less Invasive 65 Topical Treatment 65 Percutaneous Tibial Nerve Stimulation 65 Elagolix 65 Long Term Survival 65 Preterm Infants 65 nucleoside analog 65 TORISEL 65 Cytarabine